SMARCA4 and atrial fibrillation: As the patient refused repeat biopsy, blood genetic testing was performed, revealing EGFR L861Q mutation (AF-11.00%), EGFR L858M mutation (AF-11.94%), and other mutations including RB1 (AF-9.20%), TP53 (AF-12.97%), PTEN (AF-12.51%), and SMARCA4 (AF-0.96%).